#19. Eisai
4-6-10 Koishikawa, Bunkyo-ku
Tokyo, 112-8088, Japan
Japan
Tel: (81) 3 3817 3700
Fax: (81) 3 3811 3077
www.eisai.co.jp
| Headcount |
9,081 |
|
| Year Established |
1941 |
|
| Pharma Revenues |
$5,131 |
+8% |
| Total Revenues |
$5,321 |
+7% |
| Net Income |
$561 |
+9% |
| R&D Budget |
$826 |
+13% |
| Drugs Pending Approval |
| Drug |
Indication |
| rufinamide |
epilepsy |
| aricept |
severe Alzheimer’s disease |
| Drugs in Phase IIB and Beyond |
| Drug |
Indication |
| e5564 |
critical care–severe sepsis |
| Early Research Projects |
| Drug |
Indication |
| e5555 |
critical care–acute coronary syndrome |
| aciphex |
gastrointestinal disorder–extended release |
| e7080 |
cancer |
| e7974 |
cancer |
| e7820 |
cancer |
| e2012 |
Alzheimer’s disease |
| Top Selling Drugs |
| Drug |
Indication |
Sales |
(+/- %) |
| aricept |
Alzheimer’s disease |
$1,442 |
15% |
| aciphex/pariet |
proton pump-inhibitor |
$1,171 |
3% |
| zonegran |
epilepsy |
$982 |
n/a |
Account for 80% of total pharma sales.
